Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

2.0K
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
2.0K
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

1.1K
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Defining Haplosufficiency in Autosomal Recessive Limb-Girdle Muscular Dystrophy Using Molecular Markers in Disease Carriers.

Neurology. Genetics·2026
Same author

Longitudinal Psychometric Properties of the Myotonic Dystrophy Health Index in a Large Multicenter Cohort of People Living With Myotonic Dystrophy Type 1.

Muscle & nerve·2026
Same author

Toward Trial Readiness in Congenital Myotonic Dystrophy: A Longitudinal Cohort Study of Predictors of Motor Function in Childhood.

Neurology. Genetics·2026
Same author

Quantitative Measurement of Glycosylated ⍺-Dystroglycan as a Biomarker for Disease Severity in Limb-Girdle Muscular Dystrophy Type 2I/R9.

Neurology. Genetics·2026
Same author

Cooperative extension and academic departments partnership: Translating nutrition science messages to diverse audiences.

Journal of clinical and translational science·2026
Same author

Inflammation at the core: rethinking pathology in limb-girdle muscular dystrophy R3.

Brain : a journal of neurology·2026

Related Experiment Video

Updated: Sep 17, 2025

Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells
09:39

Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells

Published on: July 29, 2016

15.5K

Elevated Cancer Prevalence Identified at Specific Anatomical Sites Among People With Myotonic Dystrophy Using a

Wanfang Zhang1, Vinay Bhandaru2, Nicholas E Johnson3

  • 1Department of Epidemiology and Biostatistics, University of South Carolina, Columbia, South Carolina, USA.

Muscle & Nerve
|June 30, 2025
PubMed
Summary

Individuals with myotonic dystrophy (DM) show increased cancer risks, particularly thyroid and nonmelanoma skin cancers in DM1, and nonmelanoma skin and breast cancers in DM2. Further research is needed to understand these cancer risks by DM subtype.

Keywords:
MD STARnetSEERcancermyotonic dystrophyprevalencestandardized prevalence rate

More Related Videos

Measurements of Motor Function and Other Clinical Outcome Parameters in Ambulant Children with Duchenne Muscular Dystrophy
09:18

Measurements of Motor Function and Other Clinical Outcome Parameters in Ambulant Children with Duchenne Muscular Dystrophy

Published on: January 12, 2019

10.5K
Quantitative Magnetic Resonance Imaging of Skeletal Muscle Disease
09:30

Quantitative Magnetic Resonance Imaging of Skeletal Muscle Disease

Published on: December 18, 2016

19.7K

Related Experiment Videos

Last Updated: Sep 17, 2025

Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells
09:39

Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells

Published on: July 29, 2016

15.5K
Measurements of Motor Function and Other Clinical Outcome Parameters in Ambulant Children with Duchenne Muscular Dystrophy
09:18

Measurements of Motor Function and Other Clinical Outcome Parameters in Ambulant Children with Duchenne Muscular Dystrophy

Published on: January 12, 2019

10.5K
Quantitative Magnetic Resonance Imaging of Skeletal Muscle Disease
09:30

Quantitative Magnetic Resonance Imaging of Skeletal Muscle Disease

Published on: December 18, 2016

19.7K

Area of Science:

  • Medical research
  • Epidemiology
  • Genetics

Background:

  • Myotonic dystrophy (DM) is a genetic disorder with varying subtypes (DM1, DM2).
  • Understanding cancer risks associated with DM is crucial for patient care and screening.
  • Previous research has not fully elucidated cancer prevalence specific to DM subtypes.

Purpose of the Study:

  • To determine cancer prevalence in individuals with myotonic dystrophy (DM) using MD STARnet data.
  • To compare DM cancer prevalence against general US population rates from SEER data.
  • To identify specific cancer risks associated with different DM subtypes (DM1 and DM2).

Main Methods:

  • Retrospective cohort study analyzing 1229 individuals diagnosed with DM (2008-2019).
  • Utilized data from the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet).
  • Calculated standardized prevalence ratios (SPRs) by comparing DM cohort data with US SEER cancer data.

Main Results:

  • Individuals with DM1 showed significantly higher prevalence of thyroid, nonmelanoma skin, melanoma, and ovarian cancers.
  • DM1 patients had a 4.01-fold higher limited duration prevalence of thyroid cancer and 17.97-fold higher for nonmelanoma skin cancer.
  • DM2 patients exhibited a 34.02-fold higher limited duration prevalence of nonmelanoma skin cancer and a 2.65-fold higher complete prevalence of breast cancer.

Conclusions:

  • Myotonic dystrophy subtypes are associated with distinct cancer risks.
  • DM1 is linked to increased risks of thyroid, nonmelanoma skin, melanoma, and ovarian cancers.
  • DM2 is associated with elevated risks of nonmelanoma skin and breast cancers.
  • Larger cohort studies are necessary to further define these risks and explore underlying mechanisms.